CDC25B and esophageal squamous cell carcinoma: Our results showed that the level of circulating CDC25B-Abs had a significant relationship with the prognosis of patients with advanced ESCC (P = 0.001) (Table 3); however, the difference between CDC25B-seropositive patients and CDC25B-seronegative patients was not statistically significant in patients classified into the stage I-II (P = 0.606, log-rank; Figure 3B), T1-T2 (P = 0.320, log-rank; Figure 3D), T3-T4 (P = 0.486, log-rank; Figure 3E) and N0 (P = 0.127, log-rank; Figure 3F) subgroups.